You are here: Home » Markets » News
Business Standard

Russia ropes in Dr Reddy's to sell 100 mn Covid-19 vaccine doses; stk up 4%

Deliveries could potentially begin in late 2020 subject to completion of successful trials and registration of the vaccine by regulatory authorities in India, Dr Reddy's said in a statement

Topics
Dr Reddys | Coronavirus Vaccine | Buzzing stocks

SI Reporter  |  New Delhi 

RDIF added that it had agreed to cooperate on clinical trials and the distribution of the vaccine with the Indian firm
RDIF added that it had agreed to cooperate on clinical trials and the distribution of the vaccine with the Indian firm

Shares of Dr Reddy jumped up to 4.4 per cent to Rs 4,639 on the BSE on Wednesday after the firm said it has been roped-in by Russia-based Russian Direct Investment Fund (RDIF) to distribute 100 million Covid-19 vaccine doses in India.

"Russia's sovereign wealth fund said on Wednesday it will supply India's Dr. Reddy's Laboratories with 100 million doses of the Sputnik-V vaccine against COovid-19 once it receives regulatory approval in India," said a report by agency Reuters.

The Russian Direct Investment Fund (RDIF) added that it had agreed to cooperate on clinical trials and the distribution of the vaccine with the Indian firm, the report added.

"The agreement between RDIF and Dr Reddy’s reflects the growing awareness of countries and organizations to have a diversified anti-Covid vaccine portfolio to protect their populations" the report said quoting a statement from the fund.

"Upon regulatory approval in India, RDIF shall supply to Dr. Reddy's 100 million doses of the vaccine. The Sputnik V vaccine, which is based on wellstudied human adenoviral vector platform with proven safety, is undergoing clinical trials for the coronavirus pandemic. Deliveries could potentially begin in late 2020 subject to completion of successful trials and registration of the vaccine by regulatory authorities in India," Dr Reddy's Labs said in a press release. READ HERE

"The Phase I and II results have shown promise, and we will be conducting Phase-III trials in India to meet the requirements of the Indian regulators. Sputnik V vaccine could provide a credible option in our fight against COVID 19 in India," said G V Prasad, CEO Dr Reddy's in a statement.

At 2:59 pm, the stock was trading 3.9 per cent higher at Rs 4,618.75 per share as against 0.77 per cent rise in the S&P BSE Sensex.

India on Tuesday crossed the grim 5-million mark by recording 90,123 cases in the last 24-hours. With this, India is rapidly nearing the US tally of 6.7 million. The death toll has risen by 1,283 to 82,091.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, September 16 2020. 15:02 IST
RECOMMENDED FOR YOU
.